| Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy D Dingli, S Ailawadhi, PL Bergsagel, FK Buadi, A Dispenzieri, R Fonseca, ... Mayo Clinic Proceedings 92 (4), 578-598, 2017 | 147 | 2017 |
| Palliation of malignant dysphagia in esophageal cancer: a literature-based review. M Javle, S Ailawadhi, GY Yang, CE Nwogu, MD Schiff, HR Nava The journal of supportive oncology 4 (8), 365-73, 379, 2006 | 141 | 2006 |
| IAP antagonists induce anti-tumor immunity in multiple myeloma M Chesi, NN Mirza, VM Garbitt, ME Sharik, AC Dueck, YW Asmann, ... Nature medicine 22 (12), 1411-1420, 2016 | 140 | 2016 |
| Treatment of immunoglobulin light chain amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement A Dispenzieri, F Buadi, SK Kumar, CB Reeder, T Sher, MQ Lacy, RA Kyle, ... Mayo Clinic Proceedings 90 (8), 1054-1081, 2015 | 138 | 2015 |
| Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study FX Mahon, C Boquimpani, DW Kim, N Benyamini, NCD Clementino, ... Annals of internal medicine 168 (7), 461-470, 2018 | 125 | 2018 |
| Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016 P Kapoor, SM Ansell, R Fonseca, A Chanan-Khan, RA Kyle, SK Kumar, ... JAMA oncology 3 (9), 1257-1265, 2017 | 124 | 2017 |
| Serotonin syndrome caused by interaction between citalopram and fentanyl S Ailawadhi, KW Sung, LA Carlson, MR Baer Journal of clinical pharmacy and therapeutics 32 (2), 199-202, 2007 | 109 | 2007 |
| Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement WI Gonsalves, FK Buadi, S Ailawadhi, PL Bergsagel, AA Chanan Khan, ... Bone marrow transplantation 54 (3), 353-367, 2019 | 97 | 2019 |
| Outcome disparities in multiple myeloma: a SEER‐based comparative analysis of ethnic subgroups S Ailawadhi, IT Aldoss, D Yang, P Razavi, W Cozen, T Sher, ... British journal of haematology 158 (1), 91-98, 2012 | 95 | 2012 |
| A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE®(bispecific T-cell engager) molecule, in relapsed … SJ Harrison, MC Minnema, HC Lee, A Spencer, P Kapoor, D Madduri, ... Blood 136, 28-29, 2020 | 86 | 2020 |
| Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics P Razavi, KA Rand, W Cozen, A Chanan-Khan, S Usmani, S Ailawadhi Blood cancer journal 3 (6), e121-e121, 2013 | 72 | 2013 |
| Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and/or refractory multiple myeloma S Jagannath, LT Heffner Jr, S Ailawadhi, NC Munshi, TM Zimmerman, ... Clinical Lymphoma Myeloma and Leukemia 19 (6), 372-380, 2019 | 71 | 2019 |
| Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia J Paludo, JP Abeykoon, A Shreders, SM Ansell, S Kumar, S Ailawadhi, ... Annals of hematology 97, 1417-1425, 2018 | 66 | 2018 |
| Targeted inhibition of the deubiquitinating enzymes, USP 14 and UCHL 5, induces proteotoxic stress and apoptosis in W aldenström macroglobulinaemia tumour cells K Chitta, A Paulus, S Akhtar, MKK Blake, TR Caulfield, AJ Novak, ... British journal of haematology 169 (3), 377-390, 2015 | 63 | 2015 |
| Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised … SZ Usmani, A Hoering, S Ailawadhi, R Sexton, B Lipe, SF Hita, J Valent, ... The Lancet Haematology 8 (1), e45-e54, 2021 | 62 | 2021 |
| Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER‐medicare analysis S Ailawadhi, RD Frank, P Advani, A Swaika, M Temkit, R Menghani, ... Cancer medicine 6 (12), 2876-2885, 2017 | 61 | 2017 |
| Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib SK Kumar, BR LaPlant, CB Reeder, V Roy, AE Halvorson, F Buadi, ... Blood, The Journal of the American Society of Hematology 128 (20), 2415-2422, 2016 | 61 | 2016 |
| Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis S Ailawadhi, K Parikh, S Abouzaid, Z Zhou, W Tang, Z Clancy, C Cheung, ... Blood advances 3 (20), 2986-2994, 2019 | 60 | 2019 |
| Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials S Ailawadhi, S Jacobus, R Sexton, AK Stewart, A Dispenzieri, ... Blood cancer journal 8 (7), 67, 2018 | 59 | 2018 |
| A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and/or refractory CD–56-positive multiple … S Ailawadhi, KR Kelly, RA Vescio, S Jagannath, J Wolf, M Gharibo, T Sher, ... Clinical Lymphoma Myeloma and Leukemia 19 (1), 29-34, 2019 | 56 | 2019 |
